Company Filing History:
1 out of 560 
1 out of 260 
Years Active: 2019
Title: Amaia Lujambio: Innovator in Cancer Treatment
Introduction
Amaia Lujambio is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer research, particularly in the development of methods for identifying CDK9 inhibitors. Her work aims to improve treatment options for patients suffering from various types of cancer.
Latest Patents
Amaia Lujambio holds 1 patent for her innovative method titled "Method and kits for identifying of CDK9 inhibitors for the treatment of cancer." This patent describes a method for determining sensitivity to cancer treatment by assessing the presence of overexpression of MYC in a biological sample from a patient. The presence of MYC overexpression indicates sensitivity to treatment with a CDK9 inhibitor, specifically for cancers such as carcinoma, leukemia, and lymphoma.
Career Highlights
Throughout her career, Lujambio has worked with esteemed institutions, including Memorial Sloan Kettering Cancer Center and St. Jude Children's Research Hospital. Her research has focused on advancing the understanding of cancer biology and improving therapeutic strategies.
Collaborations
Amaia has collaborated with notable scientists in her field, including Scott William Lowe and Charles J. Sherr. These partnerships have contributed to her research and the development of innovative cancer treatments.
Conclusion
Amaia Lujambio is a trailblazer in cancer research, with her patented methods offering new hope for patients. Her dedication to advancing medical science continues to make a significant impact in the fight against cancer.